What the FDA labels say about taking them together
Atazanavir and nevirapine
Atazanavir's FDA label of August 6, 2025 names nevirapine in its contraindications section, and nevirapine's label names atazanavir too. The nevirapine label: “Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the nevirapine FDA label on DailyMed (effective July 15, 2026, Mylan Pharmaceuticals Inc.).
What does the atazanavir label say about nevirapine?
Atazanavir label, contraindicationsDrug Class: Non-nucleoside Reverse Transcriptase Inhibitors; Drugs within class that are contraindicated with atazanavir capsules: Nevirapine
Atazanavir label, drug interactionsConcomitant Drug Class/Specific Drugs: nevirapine; Effect on Concentration of Atazanavir or Concomitant Drug: ↓ atazanavir ↑ nevirapine; Clinical Comment: Coadministration of atazanavir with nevirapine is contraindicated due to the potential loss of virologic response and development of resistance, as well as the potential risk for nevirapine-associated adverse reactions [see ].
Source: FDA drug label (Reyataz, NDA021567), E.R. Squibb & Sons, L.L.C., effective December 5, 2024 (SPL set 165cff62-b284-4a27-a65d-9ec8a5bfcdd8), via openFDA
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the nevirapine label say about atazanavir?
Nevirapine label, drug interactionsDrug Name: Atazanavir/Ritonavir The interaction between nevirapine and the drug was evaluated in a clinical study. All other drug interactions shown are predicted.; Effect on Concentration of Nevirapine or Concomitant Drug: ↓ Atazanavir ↑ Nevirapine; Clinical Comment: Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure and there is a potential risk for nevirapine-associated toxicity due to increased nevirapine exposures.
Source: FDA drug label (Nevirapine), Mylan Pharmaceuticals Inc., effective July 15, 2026 (SPL set c6e93829-7024-48f6-8023-da6ff27dfc0a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Nevirapine | |
|---|---|---|
| Labeled for | HIV | HIV |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.147 per tablet 200 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once